These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 21813007)

  • 1. Adherence to and appropriateness of anti-osteoporotic treatments in patients aged 50 and over in the Valencia Region (Spain). The ESOSVAL-AD study.
    Sanfélix-Gimeno G; Sanfélix-Genovés J; Peiró S; Hurtado I; Trillo JL; Usó R; Ruiz VG; de la Torre MP; Ferreros I
    BMC Musculoskelet Disord; 2011 Aug; 12():178. PubMed ID: 21813007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a population-based prediction scale for osteoporotic fracture in the region of Valencia, Spain: the ESOSVAL-R study.
    Sanfélix-Genovés J; Peiró S; Sanfélix-Gimeno G; Giner V; Gil V; Pascual M; Fluixá C; Fuertes A; Hurtado I; Ferreros I
    BMC Public Health; 2010 Mar; 10():153. PubMed ID: 20334639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort.
    Sanfélix-Genovés J; Sanfélix-Gimeno G; Peiró S; Hurtado I; Fluixà C; Fuertes A; Campos JC; Giner V; Baixauli C
    Osteoporos Int; 2013 Mar; 24(3):1045-55. PubMed ID: 22618269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of a multifaceted intervention to improve the clinical management of osteoporosis. The ESOSVAL-F study.
    Sanfélix-Genovés J; Peiró S; Sanfélix-Gimeno G; Hurtado I; Pascual de la Torre M; Trillo-Mata JL; Giner-Ruiz V
    BMC Health Serv Res; 2010 Oct; 10():292. PubMed ID: 20964817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact on the population of different bone mineral density testing criteria and appropriateness of densitometries in the ESOSVAL cohort, Spain.
    Hurtado I; Sanfélix-Gimeno G; Baixauli-Pérez C; Peiró S; Sanfélix-Genovés J
    J Clin Endocrinol Metab; 2014 Jan; 99(1):142-50. PubMed ID: 24384018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
    Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
    BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up.
    Belhassen M; Confavreux CB; Cortet B; Lamezec L; Ginoux M; Van Ganse E
    Osteoporos Int; 2017 Mar; 28(3):853-862. PubMed ID: 27766368
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variations in osteoporosis medication utilization. A population-based ecological cross-sectional study in the region of Valencia, Spain.
    Sanfélix-Gimeno G; Juliá-Sanchis ML; Librero J; Peiró S; García-Sempere A
    PLoS One; 2018; 13(6):e0199086. PubMed ID: 29927952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance.
    Foster SA; Foley KA; Meadows ES; Johnston JA; Wang SS; Pohl GM; Long SR
    Osteoporos Int; 2011 Feb; 22(2):551-7. PubMed ID: 20798929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential impact of new National Osteoporosis Foundation guidance on treatment patterns.
    Dawson-Hughes B; Looker AC; Tosteson AN; Johansson H; Kanis JA; Melton LJ
    Osteoporos Int; 2010 Jan; 21(1):41-52. PubMed ID: 19705046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secular trends of use of anti-osteoporotic treatments in Spain: A population-based cohort study including over 1.5million people and more than 12years of follow-up.
    Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Álvarez-Gutiérrez A; Montero-Corominas D
    Bone; 2017 Dec; 105():292-298. PubMed ID: 28890137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cessation rate of anti-osteoporosis treatments and risk factors in Spanish primary care settings: a population-based cohort analysis.
    Martín-Merino E; Huerta-Álvarez C; Prieto-Alhambra D; Montero-Corominas D
    Arch Osteoporos; 2017 Dec; 12(1):39. PubMed ID: 28401495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between osteoporosis treatment change and adherence, incident fracture, and total healthcare costs in a Medicare Advantage Prescription Drug plan.
    Ward MA; Xu Y; Viswanathan HN; Stolshek BS; Clay B; Adams JL; Kallich JD; Fine S; Saag KG
    Osteoporos Int; 2013 Apr; 24(4):1195-206. PubMed ID: 23100119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis Study.
    Berry SD; Kiel DP; Donaldson MG; Cummings SR; Kanis JA; Johansson H; Samelson EJ
    Osteoporos Int; 2010 Jan; 21(1):53-60. PubMed ID: 19937426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How the knowledge of fracture risk might influence adherence to oral therapy of osteoporosis in Italy: the ADEOST study.
    Gonnelli S; Caffarelli C; Rossi S; Di Munno O; Malavolta N; Isaia G; Muratore M; D'Avola G; Gatto S; Minisola G; Nuti R
    Aging Clin Exp Res; 2016 Jun; 28(3):459-68. PubMed ID: 26873817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compliance and persistence with oral bisphosphonates for the treatment of osteoporosis in female patients with rheumatoid arthritis.
    Park JH; Park EK; Koo DW; Lee S; Lee SH; Kim GT; Lee SG
    BMC Musculoskelet Disord; 2017 Apr; 18(1):152. PubMed ID: 28399834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-adherence to anti-osteoporotic medications in Taiwan: physician specialty makes a difference.
    Yu SF; Yang TS; Chiu WC; Hsu CY; Chou CL; Su YJ; Lai HM; Chen YC; Chen CJ; Cheng TT
    J Bone Miner Metab; 2013 May; 31(3):351-9. PubMed ID: 23377623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient preferences for osteoporosis in Spain: a discrete choice experiment.
    Darbà J; Restovic G; Kaskens L; Balbona MA; Carbonell A; Cavero P; Jordana M; Prieto C; Molina A; Padró I
    Osteoporos Int; 2011 Jun; 22(6):1947-54. PubMed ID: 20838770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of adherence to osteoporosis treatment in clinical practice.
    Rossini M; Bianchi G; Di Munno O; Giannini S; Minisola S; Sinigaglia L; Adami S;
    Osteoporos Int; 2006; 17(6):914-21. PubMed ID: 16538553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.